November 25, 2025 a 12:38 pm
PFE: Analysts Ratings - Pfizer Inc.
Pfizer Inc. has been a cornerstone in the biopharmaceutical industry, consistently delivering innovative breakthroughs. Recent analyst ratings suggest a cautious optimism, with a notable emphasis on 'Hold' recommendations. This portrays a balanced sentiment with potential for long-term stability amidst emerging challenges in the biopharmaceutical landscape.
Historical Stock Grades
Below is an overview of the latest analyst ratings distribution for Pfizer as of November 2025. While the 'Hold' recommendations appear dominant, it's crucial to consider the broader market context and the potential for recovery in 'Buy' sentiment.
| Rating | Count | Score Bar |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 7 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Throughout recent months, analyst sentiment has shown a shift towards neutrality. The number of 'Hold' ratings has consistently remained high, indicating market uncertainty or a wait-and-see approach.
- The number of overall analyst ratings hasn’t fluctuated drastically, pointing towards a steady market outlook.
- 'Strong Buy' recommendations have seen a slight increase from the previous months, suggesting a cautious optimism.
- A small decline in 'Buy' ratings might reflect short-term challenges or reevaluations of expectations.
Percentage Trends
Over the past year, Pfizer's analyst ratings have gravitated more towards the middle spectrum, with 'Hold' ratings dominating. The shift from 'Strong Buy' to 'Hold' can be observed, perhaps indicating a tempered market enthusiasm.
- Strong Buy ratings decreased to 10% in November 2025 from a higher percentage earlier in the year, reflecting tempered optimism.
- Hold ratings constituted 50% of the total, underscoring a prevailing wait-and-see attitude.
- Buy ratings accounted for a stable 23%, indicating steady yet cautious investor confidence.
- Sell and Strong Sell ratings remained minimal, suggesting lack of significant bearish sentiment.
Latest Analyst Recommendations
The latest recommendations from prominent analysts reflect a general trend of maintaining existing ratings, with few changes, indicating a period of stability in perceptions of Pfizer's market standing.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-24 | Buy | Buy | Guggenheim |
| 2025-10-10 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-10-03 | Neutral | Neutral | B of A Securities |
| 2025-08-06 | Neutral | Neutral | B of A Securities |
| 2025-08-06 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Recent changes in analyst recommendations for Pfizer highlight notable adjustments, showcasing shifting sentiments in specific sectors within the financial community. Such changes provide insight into evolving market perceptions.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-08-08 | Outperform | Neutral | Daiwa Capital |
| 2024-03-22 | Hold | Buy | Argus Research |
| 2024-01-04 | Market Perform | Outperform | TD Cowen |
| 2023-10-16 | Buy | Hold | Jefferies |
Interpretation
The data indicates a moderately cautious outlook for Pfizer, influenced by stable 'Hold' and 'Buy' recommendations. The lack of significant downgrade trends suggests confidence in Pfizer’s strategic direction but also highlights a market that is closely monitoring potential risks and opportunities. Analyst sentiment reflects a justified caution rather than outright bearishness, leaving room for optimistic speculation on growth prospects.
Conclusion
Pfizer's ratings depict a nuanced market stance, balancing between cautious optimism and realistic assessments of market challenges. The high prevalence of 'Hold' ratings and minor downgrading actions underpin this sentiment. This landscape offers both opportunities for investors seeking stability and challenges for those anticipating swift upward movements in ratings. Monitoring strategic corporate actions will be crucial to navigating this complex terrain.